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RNAse treated plasmid; 3, untreated plasmid. . .  . . .  . . .  . . . . . .  . . . . . .  . . .  . . . .  1 40 
45 Double digestion of plasmid with EcoRI and HindIII. Lanes; 1 ,  Ikb 
DNA marker; 2, undigested plasmid; 3 ,  digested plasmid. . .  . . .  . . .  . . .  . 14 1  
46 PCR of recombinant plasmid. Lanes: 1 ,  plasmid with insert (489 
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A plaque-purified pseudorabies virus (PrV-mAIP) was established from a 
field isolate. Following exposure to bromodeoxyuridine (BUdR) and 
iododeoxyuridine (IUdR), six drug resistant mutants namely PrV-BUdRI, PrV-
BUdR7, PrV-BUdRlO, PrV-IUdR5, PrV-IUdR9 and PrV-I UdRlO were derived 
from PrV-mAIP. These viruses were passaged for 47 times in chicken embryo 
fibroblast (CEF) monolayer. These viruses and also including PrV-mAI P and a 
reference PrY (PrV-CD) were characterised. Differences in their eclipse phase 
and virus titres were determined based on the virus growth. Prolonged eclipse 
period (increment of 14 hrs) and reduction of the peak titres were observed in 
PrV-BUdR7, PrV-I UdR9 and PrV-I UdRIO. DNA fingerprinting of the virus 
conducted with five restriction enzymes (RE) namely BamHI, Kpnl, HindIII, 
Sad and Bglll revealed variations in the number, size and migration rate of the 
restriction fragments only for BUdR resistant mutants. Generally, the RE pattern 
of all the I UdR resistant mutants appeared similar to PrY -mAIP' perhaps PrY is 
more stable to IUdR exposure. PrV-mAIP and PrY-CD were different, probably 
XIX 
due to strain diversity of different geographical area. The absence of BamHI 
fragment 7 in both PrV-B UdRl and PrV-B UdR7 indicated highly to the loss of 
glycoprotein gE which is related to virulence. BamHI and KpnI enzymes 
appeared to be useful in discriminating the viruses. Alteration in the rate and 
type of cytopathic effect (CPE) were noticed in the viruses. The pronounced 
syncytium forming CPE in PrV-B UdR1, PrV-B UdR7 and PrV-IUdR10 indicated 
the loss of glycoprotein gC which usually plays a role in virus adsorption and 
cell to cell fusion. Similar to PrV-mAIP, the mutants were not pathogenic to 
mice. However, immunisation with these viruses conferred 100% protection 
(except PrV-B UdRlO) in mice upon challenge infection with the virulent PrY 
(PrV-CD). Mice immunised with PrV-B UdRlO produced similar antibody levels 
to those of PrV-mAIP but the degree of protection was reduced by 10%. The non 
pathogenic nature of the PrVs is known to be related to the deletion or mutation 
of the thymidine kinase (TK) gene. Thus, the 5' end of the gene of the PrVs was 
sequenced to identify any mutation. No variation was identified in the 399 bp 
nucleotide sequence data. However, the sequence showed various percentage of 
homology when pair-wise homology search were conducted against ten 
herpesviruses. Homology percentage ranged from 44.4% with herpesvirus of 
turkey (HVT) to the highly homologous (93.5%) of an established PrY strain 
NIA-3. These study demonstrate the variation among the mutants. All the 
mutants (except for PrV-B UdRlO) could be exploited for future research work 
for vaccine development. Genetic manipulation on these viruses such as 
insertion, deletion or recombination of foreign genes would be a valuable 
pathway to venture into. 
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Virus pseudorabies (PrV) PrY -mAIP telah dihasilkan melalui kaedah 
penulenan-plak ke atas satu pencilan PrY. Selepas pendedahan kepada 
bromodeoxyuridine (BUdR) dan iododeoxyuridine (IUdR), enam jenis mutan 
yang resistan iaitu PrV-BUdRI, PrV-BUdR7, PrV-BUdRIO, PrV-I UdR5, PrV-
IUdR9 dan PrV-IUdRlO telah dihasilkan daripada PrV-mAIP. Kesemua mutan 
tersebut telah dipasaj secara berterusan sebanyak 47 kali di atas sel ekalapisan 
fibroblas embrio avian. Pencirian telah dilaksanakan ke atas mutan, PrV-mAIP 
dan virus rujukan (PrV-CD). Perbedaan dari segi tempoh senyap dan titer virus 
telah diperhatikan dari replikasi virus. Peningkatan tempoh senyap ( 14  jam) dan 
penurunan titer kemuncak virus telah dipamerkan oleh PrV-BUdR7, PrV-I UdR9 
dan PrV-I UdRIO. Analisis endonukleas penyekat (AEP) dengan 5 enzim 
penyekat (BamHI, Kpnl, HmdI II, Sad dan BgnI) telah memberikan variasi dari 
segi bilangan, saiz dan kadar migrasi fragmen terbatas pada mutan yang resistan 
terhadap BUdR. Corak fragmen terbatas oleh mutan yang resistan terhadap 
IUdR menyerupai PrV-mAIP, kemungkinan virus ini lebih stabil terhadap 
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pendedahan I UdR. Variasi strain disebabkan kelainan kawasan geografi 
berkemungkinan menjadi penyebab perbedaan ketara AEP antara PrV-mAIP 
dan PrY-CD. Ketiadaan fragmen BamHI 7 pada PrV-BUdRl danPrV-BUdR7 
menunjukkan kemungkinan ketiadaan glikoprotin gE yang berkaitan dengan 
kevirulenan. Enzim BamHI dan KpnI didapati berguna untuk diskriminasi 
analisis restriksi. Pertukaran dari segi kadar dan jenis kesan sitopatik juga 
diperhatikan. Pembentukan kesan sitopatik sinsitium oleh PrV-BUdRI, PrV­
BUdR7 dan PrV-IUdRlO menunjukkan kemungkinan ketiadaan glikoprotin gC 
yang berperanan dalam penyerapan-masuk virus ke dalam sel dan fusi sel. Virus 
mutan tidak patogenik terhadap meneit seperti PrV-mAIP. Immunisasi meneit 
dengan virus-virus mutan ini (keeuali PrV-BUdRlO) memberikan perlindungan 
100%. PrV-BUdRlO menghasilkan tahap antibodi yang menyerupai PrV-mAIP, 
tetapi tahap perlindungan meneit mengalami penurunan 10%. Sifat 
ketidakpatogenikan PrY ini berkaitan dengan delesi atau mutasi terhadap gen 
thymidine kinase (TK). Oleh kerana itu, terminal 5'  gen pada kesemua PrY telah 
dijujukkan untuk mengenalpasti sebarang mutasi. Tiada perbedaan didapati pada 
jujukan bersaiz 399 bp tersebut. Jujukan ini mempamerkan perbedaan peratusan 
homologi apabila dibandingkan dengan jujukan 10 herpesvirus lain. Peratusan 
homologi serendah 44.4% dengan HVT kepada yang tertinggi (93.5%) 
diperolehi dengan PrY NLA-3. Kajian ini mempamerkan variasi diantara mutan. 
Kesemua mutan keeuali PrY -BUdR 10 berkeupayaan untuk dieksploitasikan 
untuk kajian vaksin masa depan. Manipulasi genetik terhadap virus ini seperti 





Pseudorabies virus (PrV) (synonym: porcine herpesvirus type 1 or 
Aujeszky's disease virus (ADV)) is a member of the family Herpesviridae, 
subfamily Alphaherpesvirinae. The virus infects domestic and wild animals 
(Gustafson, 1986) but not humans (Prieto, 199 1). The infection in swine is 
indigenous and wide spread, causing severe economic losses world-wide 
(Christensen, 1988). Although swine is the primary reservoir of the virus, 
other animal species including sheep, goat, cattle, dogs and cats may be 
affected (Gustafson, 1986). 
The first report of pseudorabies in scientific literature was done by 
Aujeszky ( 1902). He recovered a virus from an ox, a dog and a cat, which 
was serially transmissible to rabbits and guineapigs. The syndrome was 
described and differences from rabies were pointed out. Hanson (1954) 
suggested that the disease was present in the United States as early as ] 813. 
The serologic identity of "mad itch" as it came to be called in the United 
States, with Aujeszky' s disease was established by Shope ( 193] ). 
1 
2 
Although some countries, among them Australia, Canada and Norway 
appear to be free ofPrV, the disease is distributed world-wide and has a great 
economic impact on the pig industry (Van Oirschot et al. , 1 990). PrY causes 
multimillion dollar losses annually in the United States and other countries 
(Gustafson, 1986). For example, the estimated economic loss in The 
Netherlands was between $25-$40 million each year. In the United Kingdom, 
an acute outbreak in an unvaccinated herd cost about $250 per sow per year 
(Muirhead, 1 984). 
Infections by PrV may run an acute (Baskerville et ai., 1973) or 
subclinical course depending on the virulence of the virus and the age of the 
pig. The infection in swine is manifested by various degrees of respiratory 
distress, nervous disorders and mortality (BaskerviI1e et a!. , 1 973). Abortions 
and stil lbirth in sows, neurological disorders in piglets and respiratory signs 
in fattening pigs are the most prominent symptoms of the disease. Mortality 
in young piglets approaches 1 00%, whereas mortality in fattening pigs is 
usually less than 5% (Van Oirschot et al. , 1990a) .  Infected pigs shed PrV for 
2-3 weeks (Van Oirschot ef al. , 1 990a). 
Like other herpesviruses, PrV has the propensity to establish a latent 
infection (Sabo and Rajcani, 1 976; Beran et al. , 1 980). Latently infected 
swine should be regarded as a putative permanent source for transmission of 
PrY to other susceptible animals (Rziha et aI., 1986). Reactivation of latent 
PrY may result in excretion of the infectious virus and transmission to other 
